Original article by Yolanda Redrup
The Australian Financial Review – Page: 21 : 8-Mar-21

Biotech start-up Azura Opthalmics is seeking to develop a treatment for a type of dry eye ailment known as meibomian gland dysfunction, which impacts over 30 million people in the US alone. Meibomian gland dysfunction can occur naturally as people age, but it can also be triggered or made worse by co-morbidities such as rheumatoid arthritis. Azura Opthalmics released promising phase two clinical trial results for its treatment in the week ending 5 March, while its backers include Brandon Capital, OrbiMed and Ganot Capital.

CORPORATES
AZURA OPTHALMICS, BRANDON CAPITAL PARTNERS PTY LTD, ORBIMED ADVISORS LLC, GANOT CAPITAL